When was Emalex Biosciences founded?

Emalex Biosciences was founded in 2018 and raised its 1st funding round 2 years after it was founded.

Where is Emalex Biosciences located?

Emalex Biosciences is headquartered in Northbrook, United States.

How many employees does Emalex Biosciences have?

As of May 31, 2026, the latest employee count at Emalex Biosciences is 54.

Is Emalex Biosciences a funded company?

Emalex Biosciences is a funded company, having raised a total of $285M across 3 funding rounds to date. The company's 1st funding round was a $***** Venture Debt round, raised on Jun 03, 2020.

When was the latest funding round of Emalex Biosciences?

Emalex Biosciences' latest funding was a $***** Series D round on Nov 03, 2022, with participation from 4 investors. Its primary sector is Neurology. In United States, the Neurology sector has seen $4.63B in funding in 2026 to date.

Where does Emalex Biosciences rank among its competitors?

Emalex Biosciences ranks 72nd amongst 2919 active competitors, of which 978 are funded. It stands 3rd in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Emalex Biosciences?

Emalex Biosciences' top competitors include Jazz Pharmaceuticals, Biogen and PTC Therapeutics. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Emalex Biosciences - 2026 Company Profile, Team, Funding & Competitors

Emalex Biosciences is an acquired company based in Northbrook (United States), founded in 2018 by Jeffrey Aronin. It operates as a Developer of therapeutics for the treatment of rare and orphan neurological conditions. Emalex Biosciences has raised $285M in funding from Bain Capital Life Sciences and Paragon Biosciences. The company has 2919 active competitors, including 978 funded and 715 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Biogen and PTC Therapeutics.

Company Details

Developer of therapeutics for the treatment of rare and orphan neurological conditions. The company has developed a compound known as Ecopipam used for the treatment of pediatric Tourette Syndrome. It is a potent and selective antagonist of the human D1 receptor family.

Website: emalexbiosciences.com
Email ID: *****@emalexbiosciences.com

Key Metrics

Founded Year

2018

Location

Northbrook, United States

Stage

Acquired

Total Funding

$285M in 3 rounds

Latest Funding Round

Series D, Nov 03, 2022, $*****

Investors

Bain Capital Life Sciences & 4 more

Ranked

72^nd among 2919 active competitors

Employee Count

54 as on May 31, 2026

Investment & Acquisitions

Psyadon Pharmaceuticals

Similar Companies

Jazz Pharmaceuticals & 602 more

Exit Details

Acquired by Teva Pharmaceuticals (Apr 29, 2026)

View Emalex Biosciences' full profile

Emalex Biosciences got acquired by Teva Pharmaceuticals on Apr 29, 2026 at an acquisition amount of $*****.

Click here to take a look at Emalex Biosciences's acquisition in detail

Emalex Biosciences has raised a total funding of $285M over 3 rounds. Its first funding round was on Jun 03, 2020. Its latest funding round was a Series D round on Nov 03, 2022 for $*****. 4 investors participated in its latest round. Emalex Biosciences has 5 institutional investors.

Here is the list of recent funding rounds of Emalex Biosciences:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Nov 03, 2022	3633601	Series D	8803252	4204516	2727734	8661763
Mar 23, 2021	7632484	Series C	1432171	7735674	3413558	Valor Equity Partners & 1 more
Jun 03, 2020	5154035	Venture Debt	7732770	7377062	1807756	Horizon

Access funding benchmarks and valuations. Sign up today!

View details of Emalex Biosciences's funding rounds and investors

The founders of Emalex Biosciences is Jeffrey Aronin.

Here are the details of Emalex Biosciences' key team members:

Jeffrey Aronin: Founder of Emalex Biosciences and founder of 3 other companies, MATTER, Castle Creek Pharma and Marathon Pharma.

View details of Emalex Biosciences's Founder profiles and Board Members

Emalex Biosciences' employee count trend

Emalex Biosciences has 54 employees as of May 26. Here is Emalex Biosciences's employee count trend over the years:

Employee count trend for Emalex Biosciences

Uncover Emalex Biosciences' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Emalex Biosciences include Jazz Pharmaceuticals, Biogen and PTC Therapeutics. Here is the list of Top 10 competitors of Emalex Biosciences, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	Biogen 1978, Cambridge (United States), Public	Developer of therapies for neurodegenerative and immunology disorders	$80M	Berkshire Hathaway, Digital Pharma Lab & 11 others	78/100
3rd	PTC Therapeutics 1998, South Plainfield (United States), Public	Developer of small molecule drugs for the treatment of rare diseases	$248M	HBM Healthcare Investments, Credit Suisse First Boston ... & 28 others	77/100
4th	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
5th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	72/100
9th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
10th	Erasca 2018, San Diego (United States), Public	Developer of small molecule based therapeutics for cancer	$300M	Cormorant Asset Management, Arch Venture Partners ... & 13 others	71/100
72nd	Emalex Biosciences 2018, Northbrook (United States), Acquired	Developer of therapeutics for the treatment of rare and orphan neurological conditions	$285M	Bain Capital Life Sciences, Fidelity Investments ... & 3 others	64/100